GPR37L1 and Obesity: With the ultimate goal of assessing the viability of GPR37L1 as a clinical target for obesity, we sought to assess how the deletion of Gpr37l1 would affect the whole-body response to HFD challenge, which is known to increase markers of inflammation [44].